Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye

Gou Young Koh; Hellmut G Augustin; Peter A Campochiaro

doi:10.1016/j.molmed.2022.03.004

Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye

Trends Mol Med. 2022 May;28(5):347-349. doi: 10.1016/j.molmed.2022.03.004. Epub 2022 Apr 5.

Authors

Gou Young Koh¹, Hellmut G Augustin², Peter A Campochiaro³

Affiliations

¹ Center for Vascular Research, Institute for Basic Science, Daejeon, Republic of Korea; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea. Electronic address: gykoh@kaist.ac.kr.
² Division of Vascular Oncology and Metastasis, German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Germany; European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Germany. Electronic address: augustin@angiogenese.de.
³ Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: pcampo@jhmi.edu.

PMID: 35396185
DOI: 10.1016/j.molmed.2022.03.004

Abstract

Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.

MeSH terms

Angiogenesis Inhibitors / pharmacology
Angiogenesis Inhibitors / therapeutic use
Angiopoietin-2 / therapeutic use
Diabetic Retinopathy* / drug therapy
Humans
Macular Edema* / drug therapy
Vascular Endothelial Growth Factor A

Substances

Angiogenesis Inhibitors
Angiopoietin-2
Vascular Endothelial Growth Factor A